RT期刊文章SR电子T1的早期影响干扰素Beta-1a SC tiw与干扰素Beta-1a IM qw复发患者的MRI结果女士在《神经学研究证据(P7.257)摩根富林明乔神经病学FD Lippincott Williams &威尔金斯SP P7.257 VO 84 14补充A1安东尼红色A1马克弗里德曼A1 Juanzhi方A1阿里哈桑A1 Choon Cha A1费尔南多Da首页ngond A1 Patricia Coyle年2015 UL //www.ez-admanager.com/content/84/14_Supplement/P7.257.abstract AB目的:确定早期影响磁共振成像(MRI)结果不同干扰素Beta-1a (IFNβ-1a)皮下注射(SC) 3 x /周(tiw)与干扰素β-1a肌内(IM) 1 x /周(qw)。背景:在证据的研究中,复发多发性硬化症患者被随机分配接受干扰素β-1a 44µg SC tiw (n = 339)或干扰素β-1a 30µg IM qw (n = 338)。设计/方法:T2和前置/ post-contrast T1扫描进行筛选,研究第一天,然后每4周通过24周。结合独特的活性(CUA)病变钆增强(Gd +)或被定义为新的或扩大(主动)T2病灶。CUA数量、T2和Gd +病变/耐心/扫描(到周4、8、12、16、20、24)比较之间的事后治疗。早期临床结果MRI结果的预测价值后第一年将评估和报告。结果:平均数字CUA病变/耐心/扫描显著降低了干扰素β-1a SC与干扰素β-1a IM早在星期4使用非参数ANCOVA模型(分别为1.4和1.8;p = 0.019),早在第八周使用一个负二项模型(分别为1.1和1.6;p = 0.009)。在随后的时间点差异依然明显。 By the negative binomial model, mean numbers of active T2 lesions/patient/scan were significantly different between treatments beginning at Week 12 (p<0.05); mean numbers of Gd+ lesions/patient/scan were significantly different beginning at Week 8. CONCLUSIONS: Patients receiving IFN β-1a 44 µg SC tiw had fewer lesions than those receiving IFN β-1a 30 µg IM qw beginning as early as 4 weeks after treatment initiation. Study Supported by: EMD Serono, Inc., Rockland, MA, USA (a subsidiary of Merck KGaA, Darmstadt, Germany) and Pfizer Inc, New York, NY, USA.Disclosure: Dr. Reder received personal compensation from Acorda Therapeutics, Inc., Bayer Pharmaceuticals Corporation, Biogen Idec, EMD Serono, Genzyme Corporation, Novartis, Pfizer Inc., Questcor, Sanofi-Aventis Pharmaceuticals, and Teva Neuroscience as a consultan Dr. Freedman has received personal compensation for activities with Bayer Healthcare, Biogen Idec, Chugai, EMD Canada, Genzyme, Novartis, Sanofi-Aventis, and Teva Canada Innovation. Dr. Fang has received personal compensation for activities with EMD Serono as an employee. Dr. Hassan has received personal compensation for activities with EMD Serono as an employee. Dr. Cha has received personal compensation for activities with EMD Serono as an employee. Dr. Dangond has received personal compensation for activities with EMD Serono, Inc. an employee. Dr. Coyle has received personal compensation for activities with AbbVie, Accordant, Acorda, Bayer, Biogen, EMD Serono, Inc., Genentech, Genzyme, Mylan, Novartis, and Teva as a consultant.Thursday, April 23 2015, 2:00 pm-6:30 pm